MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijid.2021.01.032

Медицинская библиотека · International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021

Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.

Torres Antoni, Garrity-Ryan Lynne, Kirsch Courtney, Steenbergen Judith N, Eckburg Paul B, Das Anita F, Curran Marla, Manley Amy, Tzanis Evan, McGovern Paul C

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR) at post-treatment evaluation (PTE, 5-10 days after last dose). This article reports the efficacy findings, as specified in the European Medicines Agency (EMA) guidance.

METHODS

Patients were randomized 1:1 to omadacycline 100 mg intravenously (every 12 h for two doses, then every 24 h) with optional transition to 300 mg orally after 3 days, or moxifloxacin 400 mg intravenously (every 24 h) with optional transition to 400 mg orally after 3 days. The total treatment duration was 7-14 days. The primary endpoint for EMA efficacy analysis was IACR at PTE in patients with Pneumonia Patient Outcomes Research Team (PORT) risk class III and IV.

RESULTS

In total, 660 patients were randomized as PORT risk class III and IV. Omadacycline was non-inferior to moxifloxacin at PTE. The clinical success rates were 88.4% and 85.2%, respectively [intent-to-treat population; difference 3.3; 97.5% confidence interval (CI) -2.7 to 9.3], and 92.5% and 90.5%, respectively (clinically evaluable population; difference 2.0; 97.5% CI 3.2-7.4). Clinical success rates with omadacycline and moxifloxacin were similar against identified pathogens and across key subgroups.

CONCLUSIONS

Omadacycline was non-inferior to moxifloxacin for IACR at PTE, with high clinical success across pathogen types and patient subgroups.

Для цитирования: Torres Antoni, Garrity-Ryan Lynne, Kirsch Courtney, Steenbergen Judith N, Eckburg Paul B, Das Anita F, Curran Marla, Manley Amy, Tzanis Evan, McGovern Paul C. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021. DOI: 10.1016/j.ijid.2021.01.032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.